Investment Analysts’ Weekly Ratings Updates for Medtronic (MDT)

A number of firms have modified their ratings and price targets on shares of Medtronic (NYSE: MDT) recently:

• 6/5/2026 – Medtronic had its price target lowered by Rothschild & Co Redburn from $111.00 to $106.00. They now have a “buy” rating on the stock.
• 6/4/2026 – Medtronic had its price target lowered by Sanford C. Bernstein from $112.00 to $97.00. They now have an “outperform” rating on the stock.
• 6/4/2026 – Medtronic had its price target lowered by UBS Group AG from $90.00 to $85.00. They now have a “neutral” rating on the stock.
• 6/4/2026 – Medtronic had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $88.00 price target on the stock.
• 6/4/2026 – Medtronic had its “buy” rating reaffirmed by TD Cowen. They now have a $119.00 price target on the stock.
• 6/4/2026 – Medtronic had its price target lowered by JPMorgan Chase & Co. from $100.00 to $86.00. They now have a “neutral” rating on the stock.
• 6/4/2026 – Medtronic had its price target lowered by Piper Sandler from $91.00 to $85.00. They now have a “neutral” rating on the stock.
• 6/4/2026 – Medtronic had its price target lowered by Truist Financial Corporation from $95.00 to $86.00. They now have a “hold” rating on the stock.
• 6/4/2026 – Medtronic had its price target lowered by Deutsche Bank Aktiengesellschaft from $100.00 to $78.00. They now have a “hold” rating on the stock.
• 6/4/2026 – Medtronic had its price target lowered by The Goldman Sachs Group, Inc. from $84.00 to $83.00. They now have a “neutral” rating on the stock.
• 6/4/2026 – Medtronic had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $118.00 price target on the stock.
• 6/4/2026 – Medtronic had its price target lowered by Wells Fargo & Company from $114.00 to $102.00. They now have an “overweight” rating on the stock.
• 6/4/2026 – Medtronic had its price target lowered by Leerink Partners from $117.00 to $104.00. They now have an “outperform” rating on the stock.
• 6/4/2026 – Medtronic had its price target lowered by Robert W. Baird from $93.00 to $85.00. They now have a “neutral” rating on the stock.
• 6/3/2026 – Medtronic was upgraded by BTIG Research from “neutral” to “buy”. They now have a $90.00 price target on the stock.
• 6/3/2026 – Medtronic was upgraded by BTIG Research from “neutral” to “buy”. They now have a $90.00 price target on the stock.
• 6/3/2026 – Medtronic was given a new $80.00 price target by Stifel Nicolaus.
• 6/3/2026 – Medtronic had its price target lowered by Mizuho from $120.00 to $100.00. They now have an “outperform” rating on the stock.
• 6/3/2026 – Medtronic had its price target lowered by Needham & Company LLC from $120.00 to $101.00. They now have a “buy” rating on the stock.
• 5/21/2026 – Medtronic was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 5/21/2026 – Medtronic was given a new $84.00 price target by The Goldman Sachs Group, Inc.. They now have a “neutral” rating on the stock.
• 5/21/2026 – Medtronic was upgraded by The Goldman Sachs Group, Inc. to “hold”. They now have a $84.00 price target on the stock.
• 4/23/2026 – Medtronic had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $95.00 price target on the stock.
• 4/22/2026 – Medtronic had its price target lowered by UBS Group AG from $104.00 to $90.00. They now have a “neutral” rating on the stock.
• 4/21/2026 – Medtronic was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 4/15/2026 – Medtronic had its price target lowered by Truist Financial Corporation from $103.00 to $95.00. They now have a “hold” rating on the stock.
• 4/15/2026 – Medtronic had its price target raised by Robert W. Baird from $92.00 to $93.00. They now have a “neutral” rating on the stock.
• 4/13/2026 – Medtronic had its price target lowered by Mizuho from $125.00 to $120.00. They now have an “outperform” rating on the stock.

Medtronic Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 17th. Investors of record on Friday, June 26th will be given a dividend of $0.72 per share. This is a boost from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date is Friday, June 26th. This represents a $2.88 dividend on an annualized basis and a yield of 3.6%. Medtronic’s dividend payout ratio is currently 77.21%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.26% of the stock is currently owned by company insiders.

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).